热景生物(688068.SH)：创新药AA001单抗Ib期临床研究完成首例阿尔茨海默病受试者入组给药

智通财经03-02

智通财经APP讯，热景生物(688068.SH)发布公告，近日，公司收到参股公司深圳智源生物医药有限公司(以下简称“智源生物”)的全资子公司北京智源鸿晟生物医药有限公司(以下简称“智源鸿晟”)关于自主研制的创新药AA001单抗Ib期临床研究完成首例阿尔茨海默病受试者入组给药的汇报。据悉，由智源鸿晟开展的“评价AA001单抗在中国阿尔茨海默病源性轻度认知障碍和轻度阿尔茨海默病患者中安全性、耐受性和...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2616338901?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-02 16:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616338901","market":"us","top_or_hot":-1,"title":"热景生物(688068.SH)：创新药AA001单抗Ib期临床研究完成首例阿尔茨海默病受试者入组给药","media":"智通财经","content":"<div>\n<p>智通财经APP讯， 热景生物(688068.SH)发布公告，近日，公司收到参股公司深圳智源生物医药有限公司(以下简称“智源生物”)的全资子公司北京智源鸿晟生物医药有限公司(以下简称“智源鸿晟”)关于自主研制的创新药AA001单抗Ib期临床研究完成首例阿尔茨海默病受试者入组给药的汇报。据悉，由智源鸿晟开展的“评价AA001单抗在中国阿尔茨海默病源性轻度认知障碍和轻度阿尔茨海默病患者中安全性、耐受性和...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1408956.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>热景生物(688068.SH)：创新药AA001单抗Ib期临床研究完成首例阿尔茨海默病受试者入组给药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n热景生物(688068.SH)：创新药AA001单抗Ib期临床研究完成首例阿尔茨海默病受试者入组给药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-02 16:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1408956.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯， 热景生物(688068.SH)发布公告，近日，公司收到参股公司深圳智源生物医药有限公司(以下简称“智源生物”)的全资子公司北京智源鸿晟生物医药有限公司(以下简称“智源鸿晟”)关于自主研制的创新药AA001单抗Ib期临床研究完成首例阿尔茨海默病受试者入组给药的汇报。据悉，由智源鸿晟开展的“评价AA001单抗在中国阿尔茨海默病源性轻度认知障碍和轻度阿尔茨海默病患者中安全性、耐受性和...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1408956.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159992","symbol_name":"创新药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1408956.html","article_id":"2616338901","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616338901","pubTimestamp":1772439410,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯， 热景生物 发布公告，近日，公司收到参股公司深圳智源生物医药有限公司的全资子公司北京智源鸿晟生物医药有限公司关于自主研制的创新药AA001单抗Ib期临床研究完成首例阿尔茨海默病受试者入组给药的汇报。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","688068":"热景生物","BK0239":"医药制造","BK1574":"生物医药B类股","BK1161":"生物科技","06978":"永泰生物-B"},"translate_title":"Rejing Biotech (688068. SH): The phase Ib clinical study of the innovative drug AA001 monoclonal antibody completed the enrollment and administration of the first Alzheimer's disease subject","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"688068":1.5,"06978":1.5},"content_text":"智通财经APP讯， 热景生物(688068.SH)发布公告，近日，公司收到参股公司深圳智源生物医药有限公司(以下简称“智源生物”)的全资子公司北京智源鸿晟生物医药有限公司(以下简称“智源鸿晟”)关于自主研制的创新药AA001单抗Ib期临床研究完成首例阿尔茨海默病受试者入组给药的汇报。据悉，由智源鸿晟开展的“评价AA001单抗在中国阿尔茨海默病源性轻度认知障碍和轻度阿尔茨海默病患者中安全性、耐受性和初步有效性的随机、双盲、安慰剂对照、剂量递增的Ⅰb期临床试验”，是由首都医科大学宣武医院唐毅教授和魏翠柏教授牵头，全国共七家临床中心参与。研究已通过首都医科大学宣武医院伦理委员会审核，并已于近日成功完成首例受试者入组及给药。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616338901","isCrawlerRequest":true}